Nanopath, a molecular diagnostics company enabling high-quality molecular testing in minutes, has raised $10M in Series A funding, co-led by Norwest Venture Partners and the Medtech Convergence Fund. Other participants in the round include Gingerbread Capital and Green D Ventures. The new funds will support development and commercialization of Nanopath’s biosensing platform that aims to transform how women’s pelvic and gynecologic infections are diagnosed. Amogha…
